Since FGF-23 levels are higher in patients with heart failure not treated with angiotensin-converting enzyme inhibitors (ACEi) and patients in the top tercile of elevated serum FGF-23 show a lower risk of adverse events after treatment with ACEi points to the clinical importance of cross-talk between RAAS and FGF-23 [33]. Here, FGF23 is linked to heart failure.